ArticleEuropean journal of human genetics : EJHG2026
BRCA1 c.68_69del as a founder variant in the Spanish Roma: prevalence and screening implications.
Article in European journal of human genetics : EJHG, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
We hypothesized that the BRCA1 c.68_69del variant is highly prevalent among individuals with Roma ancestry from Spain due to a founder effect, as in the Ashkenazi Jewish population, where targeted screening has proven to be cost-effective. We conducted two cross-sectional prevalence studies in self-reported Roma adults from a community-based and a nationwide sample. To assess variant origin, we reconstructed haplotypes in carriers with Roma, Indian, Ashkenazi Jewish and European ancestry, and compared haplotype sharing and mutation-age estimates. BRCA1 c.68_69del variant was detected in 3.6% (16/440) of the community-based Roma sample and 0.8% (2/258) of the nationwide Roma sample. Roma carriers shared extended haplotypes (1.4-16.9 Mb) with carriers of presumed European and Ashkenazi Jewish ancestry, supporting a common founder, whereas minimal overlap (65 kb) with the Indian-ancestry carrier suggested an independent origin, despite the Roma population's Indian origin. Mutation-age estimates were 925 years ago in non-Roma carriers and 600 years ago in Roma carriers. Shared haplotypes support an Iberian founder later enriched in Roma, likely leading to a high prevalence of BRCA1 c.68_69del in Spanish Roma and supporting targeted genetic screening within this community.
Identifiers
42337332What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.